Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Travere Therapeutics Inc. Common Stock — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $44.72 (market cap $524.91M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 9.3× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Clean Edge Green Energy Idx Fd for 52 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QCLN | TVTX | |
|---|---|---|
Market Cap | $524.91M | $4.88B |
Volume | 261,814 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $68.47 | $67.52 |
52-Week Low | $41.10 | $26.79 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $47.24, showing minimal daily movement with a 0.25% gain. Technical indicators signal bearish momentum as the stock trades below key moving averages, though oversold RSI conditions suggest potential near-term support. Recent news highlights the ETF's sensitivity to political outcomes and global energy transitions, with geopolitical tensions driving renewed interest in clean energy investments.
The fund's performance remains heavily dependent on policy developments and energy market dynamics. While global renewable energy acceleration provides long-term tailwinds, near-term volatility persists due to political uncertainty and technical weakness. Investors face balanced risk-reward with policy catalysts potentially offsetting current bearish technical signals.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
